The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...
The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...
"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...